Cargando…

Novel bulking agent for faecal incontinence

BACKGROUND: Various injectable bulking agents have been used for the treatment of faecal incontinence (FI). However, encouraging early results are not maintained over time. This study aimed to assess short- and medium-term results of a new bulking agent for the treatment of FI. METHODS: The Gatekeep...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratto, C, Parello, A, Donisi, L, Litta, F, De Simone, V, Spazzafumo, L, Giordano, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229845/
https://www.ncbi.nlm.nih.gov/pubmed/21928378
http://dx.doi.org/10.1002/bjs.7699
_version_ 1782217999384576000
author Ratto, C
Parello, A
Donisi, L
Litta, F
De Simone, V
Spazzafumo, L
Giordano, P
author_facet Ratto, C
Parello, A
Donisi, L
Litta, F
De Simone, V
Spazzafumo, L
Giordano, P
author_sort Ratto, C
collection PubMed
description BACKGROUND: Various injectable bulking agents have been used for the treatment of faecal incontinence (FI). However, encouraging early results are not maintained over time. This study aimed to assess short- and medium-term results of a new bulking agent for the treatment of FI. METHODS: The Gatekeeper™ prosthesis comprises a thin solid polyacrylonitrile cylinder that becomes thicker, shorter and softer within 24 h after implantation. Fourteen patients with FI underwent treatment with Gatekeeper™ under local anaesthesia. Four prostheses were implanted in the intersphincteric space in each patient, under endoanal ultrasound guidance. Number of episodes of major FI, Cleveland Clinic FI score (CCFIS), Vaizey score, anorectal manometry, endoanal ultrasonography (EUS), health status and quality of life (Short Form 36 and Faecal Incontinence Quality of Life questionnaires) were assessed before and after treatment. RESULTS: Mean(s.d.) follow-up was 33·5(12·4) months. There were no complications. There was a significant decrease in major FI episodes from 7·1(7·4) per week at baseline to 1·4(4·0), 1·0(3·2) and 0·4(0·6) per week respectively at 1-month, 3-month and last follow-up (P = 0·002). CCFIS improved significantly from 12·7(3·3) to 4·1(3·0), 3·9(2·6) and 5·1(3·0) respectively (P < 0·001), and Vaizey score from 15·4(3·3) to 7·1(3·9), 4·7(3·0) and 6·9(5·0) respectively (P = 0·010). Soiling and ability to postpone defaecation improved significantly, and patients reported significant improvement in health status and quality of life. At follow-up, manometric parameters had not changed and EUS did not demonstrate any prosthesis dislocation. CONCLUSION: The Gatekeeper™ anal implant seemed safe, reliable and effective. Initial clinical improvement was maintained over time, and follow-up data were encouraging. Copyright © 2011 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
format Online
Article
Text
id pubmed-3229845
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher John Wiley & Sons, Ltd.
record_format MEDLINE/PubMed
spelling pubmed-32298452011-12-05 Novel bulking agent for faecal incontinence Ratto, C Parello, A Donisi, L Litta, F De Simone, V Spazzafumo, L Giordano, P Br J Surg Original Article BACKGROUND: Various injectable bulking agents have been used for the treatment of faecal incontinence (FI). However, encouraging early results are not maintained over time. This study aimed to assess short- and medium-term results of a new bulking agent for the treatment of FI. METHODS: The Gatekeeper™ prosthesis comprises a thin solid polyacrylonitrile cylinder that becomes thicker, shorter and softer within 24 h after implantation. Fourteen patients with FI underwent treatment with Gatekeeper™ under local anaesthesia. Four prostheses were implanted in the intersphincteric space in each patient, under endoanal ultrasound guidance. Number of episodes of major FI, Cleveland Clinic FI score (CCFIS), Vaizey score, anorectal manometry, endoanal ultrasonography (EUS), health status and quality of life (Short Form 36 and Faecal Incontinence Quality of Life questionnaires) were assessed before and after treatment. RESULTS: Mean(s.d.) follow-up was 33·5(12·4) months. There were no complications. There was a significant decrease in major FI episodes from 7·1(7·4) per week at baseline to 1·4(4·0), 1·0(3·2) and 0·4(0·6) per week respectively at 1-month, 3-month and last follow-up (P = 0·002). CCFIS improved significantly from 12·7(3·3) to 4·1(3·0), 3·9(2·6) and 5·1(3·0) respectively (P < 0·001), and Vaizey score from 15·4(3·3) to 7·1(3·9), 4·7(3·0) and 6·9(5·0) respectively (P = 0·010). Soiling and ability to postpone defaecation improved significantly, and patients reported significant improvement in health status and quality of life. At follow-up, manometric parameters had not changed and EUS did not demonstrate any prosthesis dislocation. CONCLUSION: The Gatekeeper™ anal implant seemed safe, reliable and effective. Initial clinical improvement was maintained over time, and follow-up data were encouraging. Copyright © 2011 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. John Wiley & Sons, Ltd. 2011-11 2011-09-16 /pmc/articles/PMC3229845/ /pubmed/21928378 http://dx.doi.org/10.1002/bjs.7699 Text en Copyright © 2011 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Original Article
Ratto, C
Parello, A
Donisi, L
Litta, F
De Simone, V
Spazzafumo, L
Giordano, P
Novel bulking agent for faecal incontinence
title Novel bulking agent for faecal incontinence
title_full Novel bulking agent for faecal incontinence
title_fullStr Novel bulking agent for faecal incontinence
title_full_unstemmed Novel bulking agent for faecal incontinence
title_short Novel bulking agent for faecal incontinence
title_sort novel bulking agent for faecal incontinence
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229845/
https://www.ncbi.nlm.nih.gov/pubmed/21928378
http://dx.doi.org/10.1002/bjs.7699
work_keys_str_mv AT rattoc novelbulkingagentforfaecalincontinence
AT parelloa novelbulkingagentforfaecalincontinence
AT donisil novelbulkingagentforfaecalincontinence
AT littaf novelbulkingagentforfaecalincontinence
AT desimonev novelbulkingagentforfaecalincontinence
AT spazzafumol novelbulkingagentforfaecalincontinence
AT giordanop novelbulkingagentforfaecalincontinence